The iQ Group Global secures worldwide license for Harvard University’s eRapid technology for at-home diagnostic testing 
Antisoma Therapeutics Pty Ltd., a medical technology company and member of The iQ Group Global, today announced it has received a worldwide license from Harvard’s Office of Technology Development to commercialise diagnostic technology developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University, with exclusivity in the fields of respiratory viral illnesses, cancer, […]
FDA Breakthrough Devices Designation application to fast-track painful finger-prick alternative for people living with diabetes
Market Announcement – The iQ Group Global Ltd The iQ Group Global Ltd (iQG Ltd) (NSX:IQG) on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), a life sciences and medical technology company, in which IQG Ltd holds 81% equity position, today announced it has filed an application with the U.S Food and Drug Administration […]
Validation study showcases success of LSBD’s rapid SARS-CoV-2 Antibody test
Market Announcement – The iQ Group Global Ltd The iQ Group Global Ltd (iQG Ltd) (NSX:IQG) on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), in which IQG Ltd holds 81% equity position, today announced the successful completion of a clinical validation study showcasing the efficacy of its rapid SARS-Cov-2 Antibody test. The results […]
Gold Technology for Immune Response Cancer Therapy Licensed to OncoTEX
OncoTEX Inc. (OncoTEX), a US oncology company and member of The iQ Group Global portfolio, is pleased to announce it has received licensing for a gold compound platform technology that induces the body’s immune system to destroy cancer cells. The technology has been developed by the University of Texas at Austin, Georgia Southern University, and […]
OncoTEX Inc. appoints Chief Executive Officer
OncoTEX Inc. (OncoTEX), a US oncology company and member of The iQ Group Global Ltd portfolio (NSX.IQG), is pleased to announce it has appointed Dr. Jonathan F. Arambula as Chief Executive Officer. Jonathan is a founding member of OncoTEX and has more than 13 years of experience in the discovery and development of cancer therapeutics […]
FDA Pre-Submission for Saliva-Based Glucose Test to Replace Invasive Finger-Prick
Market announcement – LSBD Update on Biosensor FDA Pre-Submission The iQ Group Global Ltd (NSX.IQG), on behalf of its subsidiary, Life Science Biosensor Diagnostics Pty Ltd (LSBD), is pleased to announce that one of its licensees, GBS Inc. (Nasdaq: GBS); a life sciences company operating in the Asia Pacific region, under license from LSBD to […]
New GM overseeing Farmaforce New Zealand expansion
Farmaforce appoints a new General Manager to expand its award-winning healthcare operations into New Zealand. With more than 20 years’ experience in the consumer health sector, founding member of Farmaforce, Natalie Urner, has been appointed its new General Manager. Committed to continuing to bolster the three-time award-winning sales force organisation’s reach in Australia, Natalie’s next […]
Diabetes: The World’s Largest Epidemic Unmasked
This National Diabetes Week, we are unmasking the world’s largest epidemic, Diabetes, to raise awareness about the nature of the disease and the real impact diabetes-related stigmas have on all aspects of life for people living with this disease, including their mental health and wellbeing. Diabetes is a public health problem that has reached epidemic […]
GBS Awarded $6.3 million Federal Government Science Grant to Manufacture Biosensor Technology
The iQ Group Global Ltd (NSX.IQG), on behalf of its portfolio company, GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it has been awarded a AUD $6.3 million, Australian Federal Government scientific grant to create a pilot Biosensor manufacturing facility. […]
Novel cancer-fighting drug candidate OxaliTEX issued patents in Israel and Australia
OncoTEX Inc. is pleased to report that the notice of allowance for its OxaliTEX composition patent application, originally published on January 31, 2021, has successfully passed the opposition period and is now an issued patent. OxaliTEX is being developed in Texas by US oncology company, OncoTEX Inc. (OncoTEX), a member of Australian bioscience enterprise The […]